Bridgeway Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Bridgeway Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-173,200	Closed	-$688K	–	1370
2019 Q1	$688K	Buy	173,200 +69,900	+68%	+$281K	0.01%	899
2018 Q4	$411K	Hold	103,300	–	–	0.01%	1059
2018 Q3	$711K	Hold	103,300	–	–	0.01%	1037
2018 Q2	$697K	Hold	103,300	–	–	0.01%	1021
2018 Q1	$672K	Hold	103,300	–	–	0.01%	997
2017 Q4	$460K	Hold	103,300	–	–	0.01%	1118
2017 Q3	$638K	Buy	103,300 +3,300	+3%	+$21.3K	0.01%	1015
2017 Q2	$927K	Hold	100,000	–	–	0.01%	860
2017 Q1	$928K	Hold	100,000	–	–	0.01%	839
2016 Q4	$837K	Hold	100,000	–	–	0.01%	885
2016 Q3	$687K	Buy	+100,000	New	+$610K	0.01%	953

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's OCUL Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2019, closing a stake of 173,200 shares — an estimated $688K sold.

Bridgeway Capital Management first reported a position in OCUL in Q3 2016 and held it in 11 quarters. The position peaked at $928K in Q1 2017. 68 funds tracked by Wall St. Rank hold OCUL as of Q2 2019.

Bridgeway Capital Management reported no remaining Ocular Therapeutix position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 173,200 Ocular Therapeutix shares in Q2 2019, an estimated $688K.
Bridgeway Capital Management first reported a position in Ocular Therapeutix in Q3 2016 and held it in 11 quarters.
Bridgeway Capital Management's Ocular Therapeutix position peaked at $928K in Q1 2017.
68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.